CRISPR Therapeutics’ (CRSP) Market Outperform Rating Reiterated at JMP Securities

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research report issued on Thursday,Benzinga reports. They presently have a $86.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 102.42% from the stock’s previous close.

Several other research analysts have also weighed in on the company. Truist Financial boosted their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Finally, StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $75.00.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $0.82 during trading on Thursday, hitting $42.49. The stock had a trading volume of 357,475 shares, compared to its average volume of 1,962,554. The company has a market capitalization of $3.63 billion, a PE ratio of -15.03 and a beta of 1.67. The company’s 50-day moving average price is $42.06 and its two-hundred day moving average price is $46.25. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, equities analysts anticipate that CRISPR Therapeutics will post -5.08 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. Sanctuary Advisors LLC bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at $381,000. Exchange Traded Concepts LLC lifted its position in shares of CRISPR Therapeutics by 22.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock valued at $902,000 after acquiring an additional 3,563 shares during the period. Vontobel Holding Ltd. lifted its position in shares of CRISPR Therapeutics by 3.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 16,957 shares of the company’s stock worth $797,000 after buying an additional 600 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of CRISPR Therapeutics by 56.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 13,617 shares of the company’s stock worth $640,000 after buying an additional 4,909 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth $258,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.